// App-Quantinova.ai

BSH2020‐OR‐006 : CIP2A: its validation as a predictive biomarker of subsequent progression to blast crisis in CML

Researchers

Presenter

  • C. Lucas

Principal Investigators

  • G. Austin

  • A. Holcroft

  • A. Basabrain

  • S. Loaiza

  • J. Apperley

  • C. Law

  • L. Bonnett

  • R. Clark

Medical Centers

  • Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool

  • Chester Medical School, University of Chester, Chester

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • Technology Directorate

  • Biostatistics, University of Liverpool, Liverpool, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

  • Cancerous inhibitor of protein phosphatase 2A

  • Protein Phosphatase 2 Phosphatase Activator

Drug/Treatment

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved